Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the case of the coexistence of depression and obesity, the most important changes were (1) the decrease in the membrane form of GLUT4, which may suggest weaker insulin action in the frontal cortex, and (2) the diminished GLP-1R, which could cause neurodegenerative changes in the hippocampus.
|
31782099 |
2020 |
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
The objectives of this study were to (1) determine the expression of the insulin-sensitive GLUT4 glucose transporter and IR in the syncytiotrophoblast plasma membranes across gestation in normal pregnancy and in pregnancies complicated by maternal obesity and (2) assess the effect of insulin on GLUT4 plasma membrane trafficking in human placental explants.
|
31112275 |
2019 |
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Treatment with celastrol protects against obesity through suppression of galanin-induced fat intake and activation of PGC-1α/GLUT4 axis-mediated glucose consumption.
|
30742994 |
2019 |
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the late 1980s, when GLUT4, the major insulin-regulated glucose transporter, was identified, my lab observed that it was downregulated in adipocytes but not in skeletal muscle in insulin-resistant states, such as obesity and type 2 diabetes, in humans and rodents.
|
30573674 |
2019 |
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Chronic nitrate supplementation in obese type 2 diabetic rats improved glucose tolerance, insulin resistance, and dyslipidemia; these favorable effects were associated with increased mRNA and protein expression of GLUT4 and decreased mRNA expression of iNOS in insulin-sensitive tissues, and with decreased gluconeogenesis, inflammation, and oxidative stress.
|
29432804 |
2018 |
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that baicalein is a powerful and promising agent for treatment of obesity and insulin resistance via Akt/GLUT4 pathway.
|
30308480 |
2018 |
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The acetone leaf extract of <i>Senna italica</i> was evaluated for its cytotoxic, antiglycation, and lipolytic effect, glucose uptake, and GLUT4 translocation and expression using published methods, while that for adipogenesis and protein expression levels of obesity related adipokines was assessed using adipogenesis assay and mouse adipokine proteome profiler kit, respectively.
|
29713364 |
2018 |
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In visceral adipose tissue of obese mice, fenofibrate decreased basal lipolysis rate and visceral adipocytes hypertrophy, and induced the expression of Glut-4, Irs1, and Cav-1 mRNA and miR-103-3p suggesting a higher insulin sensitivity of the adipocytes.
|
28926107 |
2018 |
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
PTP1B, p65 NF-κB, phospho-p65 NF-κB, IRS-1, IRβ, Akt, GLUT4 as well as basal and insulin-stimulated Tyr-IRS-1 and Ser-Akt phosphorylations were assessed by Western blotting in NW- and OB-VAT.
|
29769704 |
2018 |
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
AnkB variants that fail to restore normal lipid accumulation and GLUT4 localization in adipocytes are present in 1.3% of European Americans and 8.4% of African Americans, and are candidates to contribute to obesity susceptibility in humans.
|
29133412 |
2017 |
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that baicalin is a powerful and promising agent for treatment of obesity and insulin resistance via Akt/AS160/GLUT4 and P38MAPK/PGC1α/GLUT4 pathway.
|
28359800 |
2017 |
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest that GSE prevented the obesity and related metabolic disorders in HF-fed mice by regulating insulin sensitivity and GLUT4 expression as well as by preventing the oxidative stress and inflammation in skeletal muscle and adipose tissue.
|
28840618 |
2017 |
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, the effects of LLAE on body weight, fat mass, glucose and lipid metabolism and the expression of PPARγ2, insulin receptor substrate 1 and glucose transporter 4 (GLUT4) in visceral adipose tissue (VAT) were measured in HFD-induced obese rats treated with low or high dose [0.5 or 3.0 g crude drug/(kg.d)] LLAE for 6 weeks.
|
28690544 |
2017 |
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Enhanced GLUT4-Dependent Glucose Transport Relieves Nutrient Stress in Obese Mice Through Changes in Lipid and Amino Acid Metabolism.
|
27679559 |
2016 |
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLUT4 function is impaired in obesity and type 2 diabetes leading to hyperglycemia and an increased risk of cardiovascular disease and neuropathy.
|
25596527 |
2015 |
Obesity
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To assess the effects of excessive weight and obesity on gene-specific methylation levels of promoter regions, we determined the methylation status of four genes involved in inflammation and oxidative stress [interleukin 6 (IL6), tumor necrosis factor α (TNFα), mitochondrial transcription factor A (TFAM), and glucose transport 4 (GLUT4)] in blood cell-derived DNA from healthy women volunteers with a range of body mass indices (BMIs) by methylation-specific PCR.
|
25921605 |
2015 |
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLUT4 defects in adipose tissue are early signs of metabolic alterations in Alms1GT/GT, a mouse model for obesity and insulin resistance.
|
25299671 |
2014 |
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Mice overexpressing the Glut4 glucose transporter in adipocytes have elevated lipogenesis and increased glucose tolerance despite being obese with elevated circulating fatty acids.
|
25303528 |
2014 |
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
H(2) significantly increased skeletal muscle membrane Glut4 expression and markedly improved glycemic control in STZ-induced type 1 diabetic mice after chronic intraperitoneal (i.p.) and oral (p.o.) administration.However, long-term p.o. administration of H(2) had least effect on the obese and non-insulin-dependent type 2 diabetes mouse models.
|
23326534 |
2013 |
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our findings showed that adipose GLUT4 gene expression changes were more related to insulin resistance and type 2 diabetes rather than to obesity.
|
21604201 |
2013 |
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In normal, obese and T2D cells: A) BRS-3-AP as insulin enhanced BRS-3 and GLUT-4 mRNA/protein levels; improving glucotransporter translocation to plasma membrane, and B) BRS-3-AP caused a concentration-related-stimulation of glucose transport, being obese and T2D myocytes more sensitive to the ligand than normal.
|
23291341 |
2013 |
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, it seems that at this stage caveolins and GLUT-4 are regulated independently of the insulin pathway, through a mechanism that could be mediated by inflammation and oxidative stress associated with obesity.
|
20506294 |
2010 |
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chronic low-grade inflammation in obesity could thus contribute to insulin resistance by modulating proteins that control GLUT4 trafficking.
|
19219422 |
2009 |
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Granulosa and cumulus cells were analyzed for mRNA expression of insulin signaling components (IRS-2 and Glut4), glucose-regulated genes (ChREBP, ACC, and FAS) and insulin-regulated genes (SREBP-1, CD36, and SR-BI) associated with obesity/insulin resistance.
|
19223519 |
2009 |
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
The expression of the gene encoding RBP4 was increased in the adipose tissue, but not in the liver, of insulin-resistant adipose GLUT4(-/-) mice and five other mouse models of obesity and insulin resistance.
|
18598108 |
2008 |